Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES

• Главные авторы: Gregory P. Geba (Автор), Ruifeng Chen (Автор), Kasturi Talapatra (Автор), Taylor Brackin (Автор), Kusha A. Mohammadi (Автор), Robert Pordy (Автор), Garen Manvelian (Автор), David J. Maron (Автор), Gregory G. Schwartz (Автор), Michael Szarek (Автор), Ph. Gabriel Steg (Автор), Sergio Fazio (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2024-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of ODYSSEY OUTCOMES assessed the effect of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor...